MODERNA Inc. (MRNA) dropped 20.20 percent to $139.15 by 10:15 a.m. EDT on Aug. 20, 2026, paring gains from the previous day's explosive 177 percent rally.
The stock had surged on positive Phase 3 results for Moderna's personalized mRNA cancer vaccine, developed with Merck. The data showed the vaccine slowed melanoma spread and recurrence, pushing MRNA to a 52-week high of $176.66 on Aug. 19.
Today's pullback reflects profit-taking and analyst debate over whether the rally already priced in the upside. Simon Baker characterized the cancer data as "a great result, but not entirely unexpected," suggesting the market had front-run the positive outcome.
Wall Street moved quickly to reprice the stock. UBS raised its price target to $150 from $50—a 200 percent jump. Morgan Stanley increased its target to $89 from $39. Goldman Sachs lifted its target to $120 from $67. The aggressive repricing signals confidence in the vaccine's commercial potential but also reveals how far behind consensus estimates had been.
Moderna's market capitalization now stands at $55.554 billion on 399.24 million shares outstanding. The stock opened at $150.14 with a day high of $155.00 and day low of $136.35. Volume reached 22.56 million shares by mid-morning, below the 10-day average of 25.22 million.
Key questions for investors: How much of the Phase 3 efficacy translates to durable revenue. Pricing power in oncology remains contested—payers will demand real-world durability data before committing to list price. Watch Moderna's pipeline updates on other cancer indications and the commercial timeline for launch.
